Your Health, We Care
On March 3, 2021, the U.S. Food and Drug Administration (FDA) expanded the indication approval of Pfizer’s Lorbrena (lorlatinib) to include it as a first-line treatment for anaplastic lymphoma kinase (ALK)-positive metastatic lung cancer.
On November 2, 2018, the U.S. Food and Drug Administration (FDA) approved Lorbrena (generic name: lorlatinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have received prior treatment.
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplement···【more】
Recommended：632026-23-01
On March 3, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved the···【more】
Recommended：702026-23-01
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a head-to-head study comp···【more】
Recommended：562026-23-01
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Appli···【more】
Recommended：622026-23-01
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbrena (lorlatinib) as a···【more】
Recommended：692026-23-01
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibitor specifically deve···【more】
Recommended：682026-23-01
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the targeted anticancer therapy Lorbrena (lor···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：63
On March 3, 2021, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved the supplemental New Drug Application (sNDA) for Lorbrena (lorlatinib), expanding i···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：70
At the Presidential Symposium of the 2020 ESMO Annual Congress, results of a head-to-head study comparing lorlatinib versus crizotinib as first-line therapy for advanced ALK-positi···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：56
In December 2020, the U.S. Food and Drug Administration (FDA) accepted a supplemental New Drug Application (sNDA) for Lorbrena (lorlatinib) for the first-line treatment of patients···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：62
Pfizer recently announced that the Phase III CROWN study, which evaluates Lorbrena (lorlatinib) as a first-line treatment for patients with advanced anaplastic lymphoma kinase (ALK···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：69
Lorbrena (generic name: Lorlatinib) is a next-generation tyrosine kinase inhibitor specifically developed to combat tumors that have developed resistance to other ALK inhibitors, w···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：68
On November 19, 2020, Pfizer announced the positive results of the phase III head-to-head CROWN study, which evaluated Lorbrena (lorlatinib) versus Xalkori (crizotinib) as first-li···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：52
Pfizer Inc. recently announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s supplemental New Drug Application (sNDA) for lorlatinib (brand name: Lorb···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：71
Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for its targeted anticancer therapy Lorbrena (lor···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：51
On January 28, 2022, Pfizer Inc. announced that the European Commission (EC) had approved the marketing authorization of lorlatinib (LORVIQUA®, LORBRENA®) as a monotherapy for the ···【more】
Article source：Lucius LaosRelease date：2026-01-23Recommended：54
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
